The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study
Authors' conclusion
Upadacitinib therapy was effective for RA in a real-world setting. Baseline CRP levels had no significant impact on the effectiveness of upadacitinib.
Study context
- Population
- Patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response or intolerance to ≥1 disease-modifying anti-rheumatic drug (DMARD), treated with upadacitinib, Germanyincluded in effectiveness analyses
- Participants
- 518 patients
- Exposure
- Baseline normal CRP vs CRP above the ULN in patients treated with upadacitinib
- Outcome
- Clinical remission (CDAI ≤2.8)
- Follow-up
- 6 months
Methodological detailsreal-world setting, 12-month
- Real-world setting
- 12-month
Main finding
As reported in the abstract
Clinical remission (CDAI ≤2.8), all patients
Patients achieving the primary endpoint (CDAI ≤2.8)
24.4%
Observational data: associations, not effects.
Secondary outcomes
CDAI ≤2.8 by baseline CRP · 12 months
CDAI ≤2.8 by baseline CRP · 12 months
- Similar proportions in normal CRP and CRP above ULN, also for other key secondary endpoints
Effectiveness by concomitant MTX and by prior b/tsDMARD-IR
- Comparable with and without concomitant MTX and in b/tsDMARD-naive and b/tsDMARD-IR patients
Original publication
The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study. Clin Exp Rheumatol. Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →